{"raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe IC50 values for BRAF and RAF1 (CRAF) kinases by Compound 1 were measured, resulting in IC50 values of 5.98 nM and 1.3 nM, respectively, as indicated in Table 1.\nTABLE 1IC50SEMKinase(nM)n(nM)BRAF5.98170.51RAF1 (CRAF)1.3\u2002180.05"}
{"final_json": [{"molecule_name": "Compound 1", "protein_target_name": "BRAF", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": "5.98", "unit": "nM"}, {"molecule_name": "Compound 1", "protein_target_name": "RAF1 (CRAF)", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": "1.3", "unit": "nM"}]}
{"raw_mentions": "Compound 1 was demonstrated to be a potent inhibitor of the RAF1, BRAF, ARAF kinases, with IC50 values <5 nM.\nKinases outside the RAF family inhibited >10% by 1 \u03bcM Compound 1 are listed in Table 3."}
{"final_json": [{"molecule_name": "Compound 1", "protein_target_name": "RAF1, BRAF, ARAF kinases", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": "<5", "unit": "nM"}, {"molecule_name": "Compound 1", "protein_target_name": "Kinases outside the RAF family", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": ">10", "unit": "%"}]}
{"raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nHSAMost synergistic area score 21.6(binimetinib: 31.2-500 nM;compound 1: 111.1-1000 nM)\nLoeweMost synergistic area score 16.2(binimetinib: 7.8-125 nM;compound 1: 37-333.3 nM)\nBlissMost synergistic area score 11.6(binimetinib: 7.8-125 nM;compound 1: 12.3-111.1 nM)"}
{"final_json": [{"molecule_name": "binimetinib", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Concentration", "value": "31.2-500", "unit": "nM"}, {"molecule_name": "compound 1", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Concentration", "value": "111.1-1000", "unit": "nM"}, {"molecule_name": "binimetinib", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Concentration", "value": "7.8-125", "unit": "nM"}, {"molecule_name": "compound 1", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Concentration", "value": "37-333.3", "unit": "nM"}, {"molecule_name": "binimetinib", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Concentration", "value": "7.8-125", "unit": "nM"}, {"molecule_name": "compound 1", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Concentration", "value": "12.3-111.1", "unit": "nM"}]}
{"raw_mentions": "None of the sentences in the provided text contain all of the required elements: a bioactivity metric (IC50, Ki, Kd, EC50), a specific numeric value associated with that metric, and a unit for that value. The text primarily discusses tumor growth inhibition (TGI) percentages, treatment doses, and tumor volumes without referencing the specified bioactivity metrics. Therefore, there are no sentences to extract based on the given criteria."}
{"raw_mentions": "Here are the extracted sentences with concrete data points that meet the specified criteria:\n\n\nDose-dependent exposures and antitumor responses to compound 1 treatment were observed. \nThe average TGI with increasing doses of 1.5, 3, 10, or 15 mg/kg BID was 42%, 58%, 85%, and 107%, respectively (Table 14). \nTABLE 14Baseline TumorFinal TumorTreatmentVolume (mm<sup>3</sup>)<sup>a</sup>Volume (mm<sup>3</sup>)\u00aa\u0394T/\u0394C (%)<sup>b</sup>TGI (%)<sup>c</sup>P-value<sup>d</sup>Vehicle304 \u00b1 311333 \u00b1 199\u2002\u2014\u2014\u20141.5 mg/kg BID compound 1304 \u00b1 35902 \u00b1 1055842&lt;0.0001*3 mg/kg BID compound 1304 \u00b1 32741 \u00b1 98\u20024258&lt;0.0001*10 mg/kg BID compound 1304 \u00b1 34463 \u00b1 53\u20021585&lt;0.0001*15 mg/kg BID compound 1304 \u00b1 33230 \u00b1 20\u2002\u22127107&lt;0.0001* \nDose-dependent tumor growth inhibition (TGI) was observed with twice daily (BID) compound 1 treatment, with low dose compound 1 (1.5-3.0 mg/kg BID) leading to moderate TGI (mean 42-58%) and higher compound 1 doses (10-15 mg/kg BID) to strong TGI (mean 85-107%)."}
{"final_json": [{"molecule_name": "compound 1", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "TGI", "value": "42%", "unit": "%"}, {"molecule_name": "compound 1", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "TGI", "value": "58%", "unit": "%"}, {"molecule_name": "compound 1", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "TGI", "value": "85%", "unit": "%"}, {"molecule_name": "compound 1", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "TGI", "value": "107%", "unit": "%"}, {"molecule_name": "compound 1", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "TGI", "value": "42-58%", "unit": "%"}, {"molecule_name": "compound 1", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "TGI", "value": "85-107%", "unit": "%"}]}
{"raw_mentions": "There are no sentences that meet the specified criteria."}
